J&J, Basilea To File Ceftobiprole For Hospital-Acquired Pneumonia
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Basilea Pharmaceuticals plans to file the antibiotic ceftobiprole "as soon as possible" for the treatment of hospital-acquired pneumonia and community-acquired pneumonia requiring hospitalizations following positive Phase III results, CEO Anthony Man stated during an Oct. 9 conference call announcing the results
You may also be interested in...
J&J/Basilea ceftobiprole positive Phase III data
Swiss firm Basilea announces positive results for its first-in-class antibiotic ceftobiprole. The antibiotic met its primary endpoint of statistical noninferiority versus combination therapy in complicated skin and skin structure infections (cSSSIs) in a second pivotal Phase III trial (STRAUSS II) in resistant Staphylococcus aureus skin infections. Data indicate that single-agent ceftobiprole was as effective as a combination regimen of standard broad-spectrum agents, the company said. Johnson & Johnson licensed rights to the broad-spectrum cephalosporin from Basilea in February 2005 (1Pharmaceutical Approvals Monthly February 2005, p. 19)...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.